Hybrid Revascularization or Conventional Surgery: History Is Still Being Written

Hybrid revascularization seems to achieve results similar to those of conventional myocardial revascularization surgery at 5 years, although studies published so far do not seem to be enough for a definitive answer.

revascularizacion incompleta en cirugia no cardiacaThis new work, soon to be published in J Am Coll Cardiol Intv, has had promising results in selected patients with multivessel disease; however, we will have to wait for adequately powered randomized studies to add hybrid revascularization to our therapeutic toolbox.

 

One-year results from the POL-MIDES (HYBRID) study showed the feasibility of hybrid revascularization among 200 patients with anterior descending artery lesion and a lesion >70% in at least one other major epicardial vessel. All patients were candidates for surgery or angioplasty.


Read also: Do the Best Coronary Revascularization Prior TAVR.


This new publication brings us the 5-year results, which showed similar mortality among hybrid revascularization and conventional myocardial revascularization surgery (6.4% vs. 9.2%; p = 0.69) as well as similar rates of acute myocardial infarction (4.3% vs. 7.2%; p = 0.30), repeat revascularization (37.2% vs. 45.4%; p = 0.38), stroke (2.1% vs. 4.1%; p = 0.35), or combined events (45.2% vs. 45.4%; p = 0.39).

 

No differences between strategies were observed, either, after patients were stratified by both EuroSCORE and SYNTAX score tertiles.

 

In reality, this technique entails a certain learning curve for surgeons, and not everyone is willing to try it, particularly if there are no significant differences in outcomes when compared with conventional surgery.


Read also: Complete Revascularization Is Beneficial in Acute MI with Cardiogenic Shock.


This is also added to practical limitations as regards logistics, such as a lack of hybrid operation rooms versus a procedure than can be performed in stages, cooperation and collaboration of surgical and interventional teams, risk of bleeding due to the use of antiplatelet and antithrombotic therapy, and difficulties in the assessment of cost-effectiveness. In conclusion, the use of hybrid revascularization will remain uncommon until there is more convincing evidence in its favor.

 

Original title: Hybrid Coronary Revascularization in Selected Patients with Multivessel Disease – 5 Year Clinical Outcomes of the Prospective Randomized Pilot Study.

Reference: Tajstra M et al. J Am Coll Cardiol Intv 2018; Epub ahead of print.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

TCT 2024 | Use of Drug-Coated Balloons for Side Branch Treatment in Provisional Stenting

In some cases, treating coronary bifurcations with provisional stenting requires side branch stenting, which may lead to suboptimal outcomes. Drug-coated balloons (DCBs) have emerged...

TCT 2024 | Use of Artificial Intelligence for Patients with Suspected Coronary Artery Disease

The current approach to chest pain mainly focuses on symptom characteristics, conducting functional tests for ischemia assessment. However, several randomized clinical trials have shown...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...